rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    INDV
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Supernus undervalued after Indivior merger, says Bank of America
      Nov 9Yahoo FinanceINDVSUPNBAC
      Supernus resumed at overweight at Piper Sandler on Indivior merger
      Nov 4Seeking AlphaINDVSUPNPIPR
      Supernus Pharmaceuticals (SUPN) After Its Indivior Merger Looks Undervalued

      Supernus Pharmaceuticals (SUPN) just completed its all‑stock merger with Indivior Pharmaceuticals, creating Supernus, Inc., and simultaneously requested delisting of its legacy shares after multiple index removals connected to the transaction. Recent trading tells a mixed story for Supernus Pharmaceuticals. The share price closed at $41.92 after a 7 day share price return of 2.34%, yet the 90 day share price return declined 10.64% and the 1 year total shareholder return fell 26.46%. However,...

      Nov 4Yahoo FinanceINDVSUPN
      Why Indivior Pharmaceuticals Stock Topped the Market Today | The Motley Fool

      The company is merging with a peer.

      Nov 2The Motley FoolINDV
      Supernus Pharmaceuticals Completes Merger With Indivior Pharmaceuticals
      Nov 2Yahoo FinanceINDVSUPN
      Supernus and Indivior Complete Merger Creating a Diversified CNS Biopharmaceutical Leader
      Nov 2Yahoo FinanceINDV
      SUPN Q3 deep dive: robust portfolio growth and integration priorities amid Indivior merger
      Nov 1Yahoo FinanceINDVSUPN
      Indivior Pharmaceuticals (INDV) Could Be 30% Undervalued On Its Turnaround Narrative
      Oct 30Yahoo FinanceINDV
      Indivior Pharmaceuticals (INDV) Shareholders Back Merger After Record Third Quarter
      Oct 30Yahoo FinanceINDV
      Indivior Shares Rise After Q3 Adjusted EPS, Revenue Top Estimates
      Oct 29Yahoo FinanceINDV
      Indivior Pharmaceuticals Inc. (INDV) Beats Q3 Earnings and Revenue Estimates
      Oct 29Yahoo FinanceINDV
      Indivior Reports Third Quarter 2026 Financial Results

      Q3’26 Total Net Revenue of $356 Million, Up 13% YoYRecord Quarterly Total SUBLOCADE® Net Revenue of $267 Million in Q3'26, Up 22% YoY Record Quarterly Net Income of $137 Million and Record Non-GAAP Net Income of $161 Million in Q3'26Record Quarterly Adjusted EBITDA of $211 Million in Q3'26, Up 76% YoYNet Income Margin of 39%, up 2,500 basis points YoY, Adjusted EBITDA Margin of 59%, Up 2,100 Basis Points YoYOn Track to Close Merger with Supernus on November 2nd RICHMOND, Va., Oct. 29, 2026 (GLOB

      Oct 29Yahoo FinanceINDV
      Indivior earnings up next: Can SUBLOCADE sustain momentum?
      Oct 28Investing.comINDV
      Supernus Pharmaceuticals ends UBS credit line ahead of Indivior merger
      Oct 26Investing.comINDVSUPNUBS
      Indivior to Report Third Quarter 2026 Financial Results
      Oct 19Yahoo FinanceINDV
      Indivior: SUBLOCADE Growth And Improving Profitability Create Upside Potential (INDV)
      Oct 14Seeking AlphaINDV
      Indivior, Supernus advance merger amid disclosure updates

      Detailed price information for Indivior Pharmaceuticals Inc (INDV-Q) from The Globe and Mail including charting and trades.

      Oct 7The Globe and MailINDVSUPN
      Addex Regains Rights to GABAB Positive Allosteric Modulator Portfolio from Indivior

      Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, September 25, 2026 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company developing novel small molecule allosteric modulators for neurological disorders, today announced that it has regained full global rights to all GABAB positive allosteric modulator (PAM) assets discovered under its research collaboration with Indivior UK Limited (“Indivior”). The return of the rights follows Indivior’s ra

      Sep 25Yahoo FinanceINDV
      Addex Regains Rights to GABAB Positive Allosteric Modulator Portfolio from Indivior
      Sep 24Yahoo FinanceADXNINDV
      Indivior (INDV) Receives a Rating Update from a Top Analyst

      Detailed price information for Indivior Pharmaceuticals Inc (INDV-Q) from The Globe and Mail including charting and trades.

      Sep 19The Globe and MailINDV
      Indivior Sets Special Cash Dividend at $8.13 a Share Contingent on Completion of Supernus Merger
      Sep 17Yahoo FinanceINDVSUPN
      Indivior declares $8.13 special dividend contingent on merger
      Sep 17Investing.comINDV
      Indivior Pharmaceuticals, Inc. Declares Special Cash Dividend
      Sep 17Yahoo FinanceINDV
      Indivior Terminates Supply Agreement With Reckitt Benckiser
      Sep 16Yahoo FinanceINDV
      Indivior Pharmaceuticals to end supply agreement with Reckitt Benckiser in January
      Sep 15Investing.comINDV
      Indivior Pharmaceuticals Inc. (INDV) Down 5.3% Since Last Earnings Report: Can It Rebound?

      Indivior Pharmaceuticals Inc. (INDV) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

      Sep 2Yahoo FinanceINDV
      Indivior Pharmaceuticals Inc. (INDV) Loses 12.9% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

      Indivior Pharmaceuticals Inc. (INDV) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

      Aug 31Yahoo FinanceINDV
      Indivior PLC Earnings Call: Merger, Margins and Growth

      Detailed price information for Indivior Pharmaceuticals Inc (INDV-Q) from The Globe and Mail including charting and trades.

      Aug 23The Globe and MailINDV
      Indivior Pharmaceuticals (INDV) Could Be 30% Undervalued On Its Cost Reset Plan

      Indivior Pharmaceuticals (INDV) recently drew investor attention after a period of mixed share performance, with the stock down 9% over the past month but still higher year to date. This move has prompted fresh questions about valuation. See our latest analysis for Indivior Pharmaceuticals. At the current share price of $36.87, Indivior Pharmaceuticals has seen short term momentum fade, with a 1 month share price return that declined 8.85%, although the 1 year total shareholder return of...

      Aug 22Yahoo FinanceINDV
      Indivior's Supernus Merger Could Broaden Its Growth Engine in 2026

      Detailed price information for Alkermes Plc (ALKS-Q) from The Globe and Mail including charting and trades.

      Aug 21The Globe and MailINDV
      Should Investors Buy INDV as Sublocade Growth Meets Rising Risks?

      Indivior's Sublocade growth and cost cuts are lifting earnings and cash flow, but pipeline setbacks, legal risks and valuation add caution.

      Aug 21Yahoo FinanceINDV

      This is the newest page. Registered accounts read further back.